Navigation Links
Telik Announces Preclinical Presentations at AACR Annual Meeting

PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that four abstracts highlighting results from its Research and Development programs will be presented at the 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego.
Details of the presentations are as follows:

-- Identification and Characterization of Novel Tyrosine Kinase Inhibitors

Targeting Vascular Endothelial Growth Factor Receptor 2; Sunday, April

13, 2008, 1:00 - 5:00pm; Experimental and Molecular Therapeutics 10;

Abstract # 1439

-- Mechanism of Induction of Apoptosis by TLK199 (Telintra(R)) in Human

Leukemia Cell Lines; Monday, April 14, 2008, 8:00am - 12noon;

Experimental and Molecular Therapeutics 10; Abstract # 2270

-- Identification of a Novel Class of Nonpeptidyl Small-Molecule

Inhibitors of the Human Proteasome; Monday, April 14, 2008,

1:00 - 5:00pm; Experimental and Molecular Therapeutics 28;

Abstract # 3271

-- Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug

Discovery at Telik; Tuesday, April 15, 2008; 1:00 - 5:00pm; Cancer

Chemistry 11; Abstract # 4754

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
2. DARA Announces Information in Compliance with NASDAQ Rules
3. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
4. VA Announces SGLI and VGLI Premium Reductions
5. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
6. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
7. Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System
8. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
9. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
10. Smart Balance Announces Sales Organization Appointments
11. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy Products, ... heating products business. Cozy Products explains what this means for business moving forward. , ... the Cozy Products business model: to sell personal heaters that reduce energy consumption, are ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... found that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. ... , She developed the patent-pending RECOVERY BRA for added comfort and support. The ...
(Date:11/25/2015)... ... , ... Since its launch in 2012, the Regenestem brand ... therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent and ... , Organizations are required to hold a registered trademark in order to make ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015  Thanks to a donor with a ... Medical Center,s Sister Diane Grassilli Center for Women,s Health ... San Francisco . ... forward with a gift of $617,320 that allowed the ... with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) ...
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
Breaking Medicine Technology: